Zila Appoints Dr. George J. Vuturo to Its Board of Directors and Audit Committee
May 30 2007 - 8:00AM
Business Wire
Zila, Inc. (NASDAQ GM: ZILA), has appointed George J. Vuturo to its
Board of Directors. Dr. Vuturo will also join the Audit Committee
and will bring the number of Board Members to six. Dr. Vuturo, 57,
has over 28 years of experience in the pharmaceuticals industry and
is recognized as a leader in the field of medical education
technology. In 1995, Dr. Vuturo founded Designing Solutions, L.L.C.
and Professional Education Services Group, L.L.C., both are
healthcare services companies that specialize in providing
professional medical education programs to physicians, pharmacists,
dentists, nurses, and other healthcare providers. Dr. Vuturo has
served as managing partner of both companies since their inception.
From 2004 to 2005, Dr. Vuturo was a member of the Board of
Directors of QLT, Inc., a publicly-traded biopharmaceutical company
dedicated to the discovery, development, and commercialization of
innovative therapies. From 2001 to 2004, Dr. Vuturo was a member of
the Board of Directors and, at various times, served on the
Executive, Compensation, Audit and Nominations Committees of Atrix
Laboratories, Inc. Atrix Laboratories, a former publicly-traded
specialty pharmaceutical company, is focused on advanced drug
delivery. In 2005, Atrix Laboratories merged with QLT, Inc. Dr.
Vuturo received his Ph.D. in Health Care Administration from the
University of Florida, where he also received his Bachelor of
Science in Pharmacy. Additionally, Dr. Vuturo holds a B.S. in
Biology from Fairfield University. David R. Bethune, Chairman of
the Board of Zila, commented "Dr. Vuturo has extensive experience
in the healthcare and�pharmaceutical industries and serves on a
number of pharmacy and medical boards, including the Board of
Directors of the American Foundation for Pharmacy Education (AFPE),
and the National Board for the Center of Health Sciences at the
University of Florida Medical Center. He will be a valuable
addition to the Board and will contribute significantly to the
continued growth of Zila�s oral cancer detection business."
About�Zila, Inc. Zila, Inc., headquartered in Phoenix, is a
leading�oral cancer diagnostic company�focused on the prevention
and treatment of oral disease: Zila is dedicated to establishing
ViziLite� Plus as the new standard of care within the medical
community for the early detection of oral abnormalities that could
lead to cancer, with�an initial focus on the dental market through
Pro-Dentec�, a leading designer, manufacturer and marketer of Soft
Tissue Management (STM�) products. Sold�exclusively�and directly to
dental professionals, Pro-Dentec's core products include�the
Rota-dent� Professional Powered Brush, the Pro-Select3�
Piezo-Ultrasonic Scaler System and a suite of pharmaceutical STM�
products for both in-office and home-care use. Zila is also focused
on achieving regulatory approval for the next generation oral
cancer diagnostic, OraTest�, followed by the development of
additional applications of its cancer detection technologies. For
more information about Zila, visit www.zila.com. Safe Harbor
Statement This press release contains forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. These
forward-looking statements are based largely on Zila's expectations
or forecasts of future events, can be affected by inaccurate
assumptions and are subject to various business risks and known and
unknown uncertainties, a number of which are beyond the Company's
control. Therefore, actual results could differ materially from the
forward-looking statements contained herein. A wide variety of
factors could cause or contribute to such differences and could
adversely impact revenues, profitability, cash flows and capital
needs. There can be no assurance that the forward-looking
statements contained in this press release will, in fact, transpire
or prove to be accurate, and we disclaim any obligation to update
or revise any such forward-looking statements. For a more detailed
description of these and other cautionary factors that may affect
Zila's future results, please refer to the documents we file with
the Securities and Exchange Commission, including our Form 10-K for
the fiscal year ended July 31, 2006, our Current Report on Form 8-K
filed on December 28, 2006, and our Form 10-Q for the quarter ended
January 31, 2007.
Zila (NASDAQ:ZILA)
Historical Stock Chart
From May 2024 to Jun 2024
Zila (NASDAQ:ZILA)
Historical Stock Chart
From Jun 2023 to Jun 2024